Eunice S Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6532111/publications.pdf

Version: 2024-02-01

228 papers	8,273 citations	61984 43 h-index	58581 82 g-index
229 all docs	229 docs citations	229 times ranked	9844 citing authors

#	Article	IF	Citations
1	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 926-957.	4.9	451
2	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1â€“2 study. Lancet Oncology, The, 2017, 18, 1061-1075.	10.7	402
3	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 2011, 117, 3294-3301.	1.4	353
4	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 721-749.	4.9	314
5	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discovery, 2019, 9, 1050-1063.	9.4	288
6	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England Journal of Medicine, 2019, 380, 1628-1637.	27.0	274
7	Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 984-1021.	4.9	236
8	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology, 2014, 32, 1242-1248.	1.6	227
9	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2018, 19, 889-903.	10.7	205
10	Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood, 2016, 128, 1671-1678.	1.4	179
11	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. Journal of Clinical Oncology, 2012, 30, 2492-2499.	1.6	165
12	Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer, 2003, 98, 1196-1205.	4.1	154
13	Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 2010, 116, 3163-3170.	1.4	143
14	Acute Myeloid Leukemia, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1047-1055.	4.9	135
15	Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood, 2004, 104, 2893-2902.	1.4	124
16	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1193-1207.	4.9	119
17	Acute Lymphoblastic Leukemia, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1240-1279.	4.9	116
18	Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression. Leukemia and Lymphoma, 2003, 44, 1027-1035.	1.3	107

#	Article	IF	Citations
19	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Cancer, 2011, 117, 1583-1594.	4.1	103
20	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or highâ€risk MDS: Phase 2 study results. American Journal of Hematology, 2018, 93, 1301-1310.	4.1	98
21	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	7.2	97
22	Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502. Journal of Clinical Oncology, 2013, 31, 923-929.	1.6	96
23	NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research, 2018, 24, 1019-1029.	7.0	87
24	Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood, 2004, 103, 258-266.	1.4	85
25	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia, 2018, 32, 1338-1348.	7.2	80
26	Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Review of Clinical Pharmacology, 2018, 11, 549-559.	3.1	75
27	Treating acute myeloid leukemia in older adults. Hematology American Society of Hematology Education Program, 2014, 2014, 14-20.	2.5	71
28	Hypoxia-inducible factor-1Î± protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leukemia Research, 2011, 35, 579-584.	0.8	70
29	Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. American Journal of Hematology, 2015, 90, E77-9.	4.1	69
30	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1091-1102.	4.9	67
31	Myelodysplastic syndromes and autoimmune diseasesâ€"Case series and review of literature. Leukemia Research, 2013, 37, 894-899.	0.8	66
32	Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Advances, 2019, 3, 1939-1949.	5.2	63
33	Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1572-1611.	4.9	61
34	Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Research, 2018, 78, 1431-1443.	0.9	60
35	IMGN779, a Novel CD33-Targeting Antibodyâ€"Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Molecular Cancer Therapeutics, 2018, 17, 1271-1279.	4.1	60
36	Low 25(OH) vitamin D₃ levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer, 2014, 120, 521-529.	4.1	59

#	Article	IF	Citations
37	Pegasparaginase: where do we stand?. Expert Opinion on Biological Therapy, 2009, 9, 111-119.	3.1	57
38	Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 280-317.	4.9	56
39	A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology and Oncology, 2012, 5, 71.	17.0	56
40	Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models. Clinical Cancer Research, 2013, 19, 6506-6519.	7.0	56
41	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	4.6	56
42	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. Leukemia, 2019, 33, 1620-1634.	7.2	55
43	Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells. Genome Biology, 2019, 20, 37.	8.8	50
44	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1071-1071.	1.4	47
45	Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Advances, 2020, 4, 5246-5256.	5.2	45
46	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research, 2020, 26, 6132-6140.	7.0	45
47	Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S73-S79.	0.4	44
48	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Advances, 2020, 4, 696-705.	5.2	44
49	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. Blood, 2018, 132, 2736-2736.	1.4	44
50	Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 414-423.	4.9	44
51	Germline variants drive myelodysplastic syndrome in young adults. Leukemia, 2021, 35, 2439-2444.	7.2	43
52	Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 430-434.	0.4	42
53	Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Reviews, 2015, 29, 243-249.	5.7	42
54	Discontinuation of Systematic Surveillance and Contact Precautions for Vancomycin-ResistantEnterococcus(VRE) and Its Impact on the Incidence of VREfaeciumBacteremia in Patients with Hematologic Malignancies. Infection Control and Hospital Epidemiology, 2016, 37, 398-403.	1.8	40

#	Article	IF	Citations
55	Randomized trial of 10 days of decitabine Â± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Advances, 2018, 2, 3608-3617.	5.2	39
56	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020, 34, 2903-2913.	7.2	38
57	Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news?. American Journal of Hematology, 2015, 90, 62-72.	4.1	37
58	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4641-E4647.	7.1	36
59	Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2016, 25, 771-780.	4.1	35
60	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood, 2016, 128, 1069-1069.	1.4	35
61	Is obesity a prognostic factor for acute myeloid leukemia outcome?. Annals of Hematology, 2012, 91, 359-365.	1.8	33
62	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia, 2018, 32, 2536-2545.	7.2	33
63	Myeloid blastic transformation of myeloproliferative neoplasmsâ€”A review of 112 cases. Leukemia Research, 2011, 35, 608-613.	0.8	32
64	Image cytometryâ€based detection of aneuploidy by fluorescence in situ hybridization in suspension. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 776-784.	1.5	32
65	Advances in immunotherapy for acute myeloid leukemia. Future Oncology, 2018, 14, 963-978.	2.4	32
66	Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients â‰¥60 years old. American Journal of Hematology, 2015, 90, 639-646.	4.1	31
67	Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia. Blood, 2015, 126, 2566-2566.	1.4	31
68	Clinical updates in adult acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology, 2016, 99, 189-199.	4.4	30
69	A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITDâ€“mutant acute myeloid leukemia. Blood Advances, 2020, 4, 1711-1721.	5.2	30
70	Polo-like kinase inhibitors in hematologic malignancies. Critical Reviews in Oncology/Hematology, 2016, 98, 200-210.	4.4	29
71	Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Advances, 2020, 4, 239-251.	5.2	29
72	A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies. Blood, 2018, 132, 27-27.	1.4	29

#	Article	IF	Citations
73	Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica, 2017, 102, 1391-1400.	3.5	28
74	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 580-597.	0.4	28
75	Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2015, 33, 7003-7003.	1.6	28
76	Menin Inhibitors in Acute Myeloid Leukemiaâ€"What Does the Future Hold?. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.6	28
77	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematology,the, 2021, 8, e922-e933.	4.6	27
78	Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opinion on Biological Therapy, 2015, 15, 895-908.	3.1	25
79	Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 26-26.	1.4	25
80	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). Blood, 2016, 128, 215-215.	1.4	25
81	Treating octogenarian and nonagenarian acute myeloid leukemia patientsâ€"Predictive prognostic models. Cancer, 2009, 115, 2472-2481.	4.1	24
82	Rituximabâ€refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion, 2016, 56, 970-974.	1.6	24
83	Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 137.	17.0	23
84	Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. Blood Advances, 2021, 5, 2087-2100.	5.2	23
85	Acute myeloid leukemia and diabetes insipidus with monosomy 7. Cancer Genetics and Cytogenetics, 2009, 190, 97-100.	1.0	22
86	Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline ChemotherapyIn vivoin Human Acute Myeloid Leukemia Models. Molecular Cancer Therapeutics, 2010, 9, 2737-2751.	4.1	22
87	Adjustment to Acute Leukemia: The Impact of Social Support and Marital Satisfaction on Distress and Quality of Life Among Newly Diagnosed Patients and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 298-309.	1.4	22
88	Swallowing a bitter pillâ€"oral arsenic trioxide for acute promyelocytic leukemia. Blood Reviews, 2016, 30, 201-211.	5.7	22
89	Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Molecular Therapy, 2004, 10, 574-584.	8.2	21
90	Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leukemia and Lymphoma, 2007, 48, 1053-1056.	1.3	21

#	Article	IF	Citations
91	Novel therapies for AML: a round-up for clinicians. Expert Review of Clinical Pharmacology, 2020, 13, 1389-1400.	3.1	21
92	Smoking adversely affects survival in acute myeloid leukemia patients. International Journal of Cancer, 2012, 130, 1451-1458.	5.1	20
93	Long-term response of refractory primary cold agglutinin disease to eculizumab therapy. Annals of Hematology, 2014, 93, 343-344.	1.8	20
94	Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience. Leukemia Research, 2018, 75, 29-35.	0.8	20
95	Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. Expert Review of Anticancer Therapy, 2019, 19, 273-286.	2.4	20
96	Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Reviews, 2011, 25, 139-146.	5.7	19
97	Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. Journal of Oncology Pharmacy Practice, 2012, 18, 91-96.	0.9	19
98	CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leukemia and Lymphoma, 2013, 54, 1517-1520.	1.3	19
99	Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy. Blood, 2018, 132, 902-902.	1.4	19
100	Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study. Blood, 2015, 126, 321-321.	1.4	19
101	Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Clinical Oncology, 2022, 40, 3032-3036.	1.6	19
102	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. Blood, 2016, 128, 216-216.	1.4	18
103	BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. Blood Cancer Discovery, 2022, 3, 116-135.	5.0	18
104	Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth. Cytokine, 2011, 53, 115-129.	3.2	17
105	PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. Blood Reviews, 2021, 45, 100696.	5.7	17
106	Phase 1 study of arsenic trioxide, highâ€dose cytarabine, and idarubicin to downâ€regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer, 2011, 117, 4831-4868.	4.1	16
107	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1543-1551.	1.3	16
108	Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence and Schedule. Journal of Clinical Oncology, 2012, 30, 760-761.	1.6	16

#	Article	IF	Citations
109	Pharmacological targeting of Â-catenin in normal karyotype acute myeloid leukemia blasts. Haematologica, 2015, 100, e49-e52.	3.5	16
110	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood, 2018, 132, 1452-1452.	1.4	16
111	Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Advances, 2022, 6, 1371-1380.	5.2	16
112	Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer Genetics and Cytogenetics, 2010, 202, 101-107.	1.0	15
113	Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function. Leukemia Research, 2013, 37, 822-828.	0.8	15
114	How we will treat chronic myeloid leukemia in 2016. Blood Reviews, 2015, 29, 137-142.	5.7	15
115	Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia, 2019, 33, 771-775.	7.2	15
116	Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research, 2020, 93, 106367.	0.8	15
117	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Advances, 2021, 5, 2775-2787.	5.2	15
118	Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3795-3795.	1.4	15
119	Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precision Oncology, 2022, 6, e2100309.	3.0	15
120	Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia. AAPS Journal, 2013, 15, 662-673.	4.4	14
121	Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia. Leukemia Research Reports, 2014, 3, 86-89.	0.4	14
122	What potential is there for LSD1 inhibitors to reach approval for AML?. Expert Opinion on Emerging Drugs, 2019, 24, 205-212.	2.4	14
123	Plasma Vincristine Levels Are 100-Fold Higher with MarqiboÂ® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients â‰¥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 2491-2491.	1.4	14
124	Omacetaxine mepesuccinate in chronic myeloid leukemia. Expert Opinion on Pharmacotherapy, 2014, 15, 2397-2405.	1.8	13
125	Acceptability, Feasibility, and Efficacy of a Supportive Group Intervention for Caregivers of Newly Diagnosed Leukemia Patients. Journal of Psychosocial Oncology, 2015, 33, 163-177.	1.2	13
126	Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop. Hematology American Society of Hematology Education Program, 2020, 2020, 57-66.	2.5	13

#	Article	IF	Citations
127	Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. Blood, 2008, 112, 224-224.	1.4	13
128	Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunology, Immunotherapy, 2009, 58, 415-427.	4.2	12
129	Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia. Leukemia Research Reports, 2017, 7, 36-39.	0.4	12
130	Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 6524-6531.	7.0	12
131	Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 154-162.	1.7	12
132	Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2016, 128, 342-342.	1.4	12
133	A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. Blood, 2021, 138, 2305-2305.	1.4	12
134	Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2010, 199, 15-20.	1.0	11
135	Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models. Blood, 2016, 128, 1645-1645.	1.4	11
136	Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature. Leukemia Research, 2010, 34, e194-e196.	0.8	10
137	Spontaneous Remission in an Older Patient with RelapsedFLT3ITD Mutant AML. Case Reports in Hematology, 2016, 2016, 1-7.	0.4	10
138	A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia. Leukemia Research, 2016, 43, 44-48.	0.8	10
139	Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 1965-1973.	1.3	10
140	Acute Myeloid Leukemia Secondary to Oxaliplatin Treatment for Esophageal Cancer. Clinical Colorectal Cancer, 2012, 11, 151-154.	2.3	9
141	Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?. Best Practice and Research in Clinical Haematology, 2019, 32, 101103.	1.7	9
142	Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2018, 132, 765-765.	1.4	9
143	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML).. Journal of Clinical Oncology, 2019, 37, 7059-7059.	1.6	9
144	Prognostic and Biologic Significance of Transfer RNA-Derived Small RNAs (tsRNAs) Expression in Younger Adult Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood, 2018, 132, 89-89.	1.4	9

#	Article	IF	Citations
145	Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer. Leukemia Research, 2009, 33, 1208-1211.	0.8	8
146	Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.. Journal of Clinical Oncology, 2019, 37, TPS7068-TPS7068.	1.6	8
147	Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. Leukemia Research, 2013, 37, 1468-1471.	0.8	7
148	High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure. Leukemia Research Reports, 2014, 3, 62-66.	0.4	7
149	Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 2011-2013.	1.3	7
150	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2019, 18, 1451-1459.	4.1	7
151	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Annals of Hematology, 2020, 99, 2119-2124.	1.8	7
152	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2018, 132, 30-30.	1.4	7
153	Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2017, 35, 7003-7003.	1.6	7
154	CASCADE: A phase 3, randomized, double-blind study of vadastuximab talirine (33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, TPS7066-TPS7066.	1.6	7
155	Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 962.	4.9	7
156	Interferon-Î³ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leukemia Research, 2011, 35, 275-277.	0.8	6
157	Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 2085-2088.	1.3	6
158	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.. Journal of Clinical Oncology, 2019, 37, 7058-7058.	1.6	6
159	Acute myeloid leukemia with t(5;18)(q35;q21). Cancer Genetics and Cytogenetics, 2001, 127, 71-73.	1.0	5
160	Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1369-1374.	2.0	5
161	All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis. Leukemia Research Reports, 2018, 10, 16-19.	0.4	5
162	A precision medicine classification for treatment of acute myeloid leukemia in older patients. Journal of Hematology and Oncology, 2021, 14, 96.	17.0	5

#	Article	IF	Citations
163	Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial). Blood, 2018, 132, 3027-3027.	1.4	5
164	Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy. Blood, 2018, 132, 665-665.	1.4	5
165	Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, 7027-7027.	1.6	5
166	Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis. Blood, 2021, 138, 1264-1264.	1.4	5
167	Can decreasing smoking prevalence reduce leukemia mortality?. Annals of Hematology, 2010, 89, 873-876.	1.8	4
168	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kitâ€“positive Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 113-118.	0.4	4
169	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, 2022, 107, 1034-1044.	3.5	4
170	Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. Blood, 2019, 134, 48-48.	1.4	4
171	Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients.. Blood, 2010, 116, 1041-1041.	1.4	4
172	Hypoxia-Associated Effects on Reactive Oxygen Species Generation by Human Acute Myeloid Leukemia Cells. Blood, 2011, 118, 4998-4998.	1.4	4
173	Targeting Autophagy As a Therapeutic Strategy in Acute Myeloid Leukemia. Blood, 2016, 128, 3950-3950.	1.4	4
174	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.. Journal of Clinical Oncology, 2017, 35, 7016-7016.	1.6	4
175	Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436. Cancers, 2021, 13, 5287.	3.7	4
176	Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood, 2011, 118, 3096-3096.	1.4	4
177	An Oncologistâ€™s Perspective on Metformin Use and Acute Lymphoblastic Leukemia Outcomes. Journal of Pharmacy Practice, 2015, 28, 46-47.	1.0	3
178	Bosutinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opinion on Orphan Drugs, 2015, 3, 599-608.	0.8	3
179	A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia. Leukemia Research, 2021, 107, 106588.	0.8	3
180	Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models. Blood, 2018, 132, 2647-2647.	1.4	3

#	Article	IF	Citations
181	NY-ESO-1 Vaccination in Combination with Decitabine for Patients with MDS Induces CD4+ and CD8+ T-Cell Responses. Blood, 2015, 126, 2873-2873.	1.4	3
182	A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are NaÃ¯ve, Refractory or Have Relapsed to 5-Azacitadine. Blood, 2015, 126, 93-93.	1.4	3
183	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. Scientific Reports, 2021, 11, 23284.	3.3	3
184	Gilteritinib for the treatment of patients withFLT3mutated relapsed or refractory acute myeloid leukemia. Expert Review of Precision Medicine and Drug Development, 2019, 4, 105-112.	0.7	2
185	Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAGâ€‰Â±â€‰M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. Leukemia and Lymphoma, 2021, 62, 1778-1781.	1.3	2
186	Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 3979-3979.	1.4	2
187	Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia. Blood, 2018, 132, 1398-1398.	1.4	2
188	Increased Monocytic Myeloid-Derived Suppressor Cells in the Marrow of Relapsed/Refractory Acute Myeloid Leukemia Patients Following Induction Chemotherapy. Blood, 2018, 132, 5270-5270.	1.4	2
189	DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors. Blood, 2021, 138, 4295-4295.	1.4	2
190	Targeting CD40. Leukemia and Lymphoma, 2007, 48, 229-231.	1.3	1
191	Case study interpretation-Fort Lauderdale: Case 3. , 2015, 88, 404-407.		1
192	High dose daunorubicin: New standard of care for FLT3 ITD mutant AML. Leukemia Research, 2018, 69, 87-88.	0.8	1
193	Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia. Blood, 2018, 132, 2677-2677.	1.4	1
194	Chloroquine Derivative Lys05 Overcomes Hypoxia-Induced Chemoresistance in Acute Myeloid Leukemia through Metabolic Disruption. Blood, 2018, 132, 3948-3948.	1.4	1
195	Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy. Blood, 2018, 132, 1389-1389.	1.4	1
196	The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells.. Blood, 2006, 108, 4550-4550.	1.4	1
197	CLAGÂ±M (cladribine, cytarabine, granulocyte colony stimulating factor Â± mitoxantrone) Results in High Response Rates in Older Patients with Secondary and Relapsed/Refractory Acute Myeloid Leukemia - a Single Institute Experience. Blood, 2015, 126, 1341-1341.	1.4	1
198	A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. Blood, 2015, 126, 4266-4266.	1.4	1

#	Article	IF	Citations
199	Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia. Blood, 2016, 128, 2833-2833.	1.4	1
200	Vaccination with NY-ESO-1 in Combination with Decitabine for Patients with MDS. Blood, 2016, 128, 4326-4326.	1.4	1
201	A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML): Alliance Clinical Trials in Oncology (Alliance) Historical Patient Control. Blood, 2018, 132, 1489-1489.	1.4	1
202	Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study. Blood, 2019, 134, 3501-3501.	1.4	1
203	Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2021, 138, 4435-4435.	1.4	1
204	ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN). Blood, 2021, 138, 3637-3637.	1.4	1
205	Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. Leukemia and Lymphoma, 2021, , 1-10.	1.3	1
206	Biomarker Driven Umbrella Trial of Crenolanib in Combination with Ivosidenib, Enasidenib, Venetoclax, Vyxeos and/or Salvage Chemotherapy in FLT3 Mutant AML. Blood, 2020, 136, 16-17.	1.4	1
207	Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA. Frontiers in Oncology, 2021, 11, 806243.	2.8	1
208	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 3033-3033.	1.4	0
209	Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia (pB-ALL) Detected by Comparative Genomic Hybridization.. Blood, 2007, 110, 4270-4270.	1.4	0
210	Concomitant Presentation of Acute Myeloid Leukemia (AML) and Lung Cancer. Blood, 2008, 112, 3994-3994.	1.4	0
211	Anti-Vascular and Anti-Tumor Effects of the Vascular Disrupting Agent ASA404 (DMXAA) in Human Acute Leukemia Xenograft Models. Blood, 2011, 118, 4293-4293.	1.4	0
212	Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells. Blood, 2015, 126, 1391-1391.	1.4	0
213	Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia. Blood, 2015, 126, 4930-4930.	1.4	0
214	Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2536-2536.	1.4	0
215	The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts). Blood, 2016, 128, 287-287.	1.4	0
216	Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study. Blood, 2018, 132, 2658-2658.	1.4	0

#	Article	IF	Citations
217	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). Blood, 2018, 132, 2767-2767.	1.4	0
218	Genome-Wide Association Study (GWAS) Identifies a Significant Acute Myeloid Leukemia (AML) Susceptibility Locus Near BICRA. Blood, 2018, 132, 85-85.	1.4	0
219	Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes. Blood, 2018, 132, 4366-4366.	1.4	0
220	Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor Â± Mitoxantrone (CLAG Â± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2019, 134, 1361-1361.	1.4	0
221	Novel and Emerging Treatment Strategies for Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 999-1003.	4.9	0
222	Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2021, 138, 4426-4426.	1.4	0
223	PARP Inhibition with Talazoparib Enhances DNA Damage and Anti-Leukemic Activity of Venetoclax in Preclinical Human Acute Myeloid Leukemia (AML) Models. Blood, 2021, 138, 1176-1176.	1.4	0
224	Association between the Leukemia Mortality-to-Incidence Ratio and State Geographic Healthcare Disparities in the United States. Blood, 2021, 138, 3066-3066.	1.4	0
225	Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. Blood, 2021, 138, 4066-4066.	1.4	0
226	Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT). Blood, 2020, 136, 35-36.	1.4	0
227	Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2020, 136, 20-21.	1.4	0
228	Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy. Blood, 2020, 136, 15-16.	1.4	0